CELS, University of Southampton, Southampton, UK
Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
J Med Ethics. 2021 Feb;47(2):117-118. doi: 10.1136/medethics-2020-107048. Epub 2020 Dec 17.
We thank Parker and Wright for engaging in this roundtable debate in such a spirited way. The 'Pharmacogenetic [test] to Avoid Loss of Hearing' (PALOH) Trial is the first time a genetic point of care test has been applied in the acute neonatal setting; therefore, it is not surprising that questions have been raised which require debate, discussion and clarification. Parker and Wright misattribute several assumptions to the roundtable authors, which we would like to clarify here. Since they raise wider questions about the PALOH trial itself, several of the roundtable discussants have made a joint response.
我们感谢 Parker 和 Wright 以如此激烈的方式参与这次圆桌辩论。“避免听力损失的药物遗传学检测”（PALOH）试验是首次在急性新生儿环境中应用基因即时检测技术，因此，出现需要讨论、澄清和辩论的问题并不奇怪。Parker 和 Wright 错误地将几个假设归因于圆桌会议的作者，我们希望在这里澄清一下。由于他们对 PALOH 试验本身提出了更广泛的问题，几位圆桌会议的讨论者做出了联合回应。
